Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMT -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1)	9/26/2000 6:22:39 PM
From: keokalani'nui	Respond to of 9

At first I thought it was cheap at $95m market cap. But with no cash, $1.5m a/p, lawsuit within the JV, reverse stock splits, debt to equity conversions, not yet--but almost--in the clinic with lead product, and no large developed country markets for the products I think I will wait for the 'financing event'. Too bad, its future looks as bright as, even brighter than, any preclinical company targeting sub-Sahara tropical diseases.